Spyre Therapeutics, Inc. (SYRE) Deep Dive Video

Spyre is engineering long-acting, subcutaneous “bio-better” and combination antibodies to break the IBD therapeutic ceiling—huge upside if durability and differentiation hold, but outcomes remain clinically binary.